Dr. Yu received his undergraduate degree in chemistry from Fudan University in 2001. He received his Ph.D. in Chemistry from the University of California, Berkeley in 2006 under the direction of Julie Leary, where he developed mass spectrometric approaches for the study of protein-ligand interactions. As a graduate student, he also developed a series of proteomic technologies for the study of tyrosine sulfation, a protein post-translational modification that is implicated in regulating protein-protein interactions in the extracellular space.
In 2007, Dr. Yu joined the laboratories of Steven Gygi and John Blenis in the Department of Cell Biology at Harvard Medical School for his post-doctoral training (in both quantitative proteomics and signal transduction). There he developed quantitative mass spectrometric strategies for the study of protein phosphorylation. He deployed these powerful technologies to characterize the PI3K/Akt/mTORC1 pathway, and identified their downstream signaling modules that control a variety of cellular anabolic processes.
In 2012, Dr. Yu began his independent research career as an Assistant Professor in the Department of Biochemistry at UT Southwestern Medical Center. He was promoted to Associate Professor with tenure in 2017. Throughout his career, Dr. Yu has been the recipient of numerous awards for his research, including the Tuberous Sclerosis Alliance Postdoctoral Fellowship, a CPRIT Scholar in Cancer Research award, a Virginia Murchison Linthicum Scholar in Medical Research award, a Research Scholar award from the American Cancer Society, a UT System Rising STARs Award and most recently, an R35 MIRA award from NIGMS. He has served on many NIH and DoD advisory panels, including as a current member of the NIH Enabling Bioanalytical and Imaging Technologies (EBIT) Study Section.
The long-term goals of the Yu lab are to develop cutting-edge, mass spectrometry-based proteomic technologies, and applying them to systematically identify novel protein modifications and the related "dark matter" within in the human proteome. These data-driven strategies are then combined with classical biochemistry approaches to chacterize aberrant protein modification patterns, decipher the mechanisms of their deregulation, establish the functional consequences of these molecular events, facilitate the development of relevant therapeutic strategies, and finally, identify proteomic signatures that may serve as diagnostic, prognostic or predictive biomarkers for the relevant diseases (e.g., cancer, diabetes and neurodegenerative disease).
- Fudan University (2001), Chemistry
- Graduate School
- Univ of California-Berkeley (2006), Chemistry
- Mass Spectrometry
- Post-translational Modifications (e.g. Phosphorylation and ADP-ribosylation)
- Quantitative Proteomics
- Signal Transduction/Cancer Biology and Metabolism
- mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation.
- He L, Gomes AP, Wang X, Yoon SO, Lee G, Nagiec MJ, Cho S, Chavez A, Islam T, Yu Y, Asara JM, Kim BY, Blenis J Mol. Cell 2018 May
- Proteomic analysis of the downstream signaling network of PARP1.
- Zhen Y, Yu Y Biochemistry 2018 Jan
- Post-transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 Signaling.
- Lee G, Zheng Y, Cho S, Jang C, England C, Dempsey JM, Yu Y, Liu X, He L, Cavaliere PM, Chavez A, Zhang E, Isik M, Couvillon A, Dephoure NE, Blackwell TK, Yu JJ, Rabinowitz JD, Cantley LC, Blenis J Cell 2017 Nov
- Genome-wide identification and differential analysis of translational initiation.
- Zhang P, He D, Xu Y, Hou J, Pan BF, Wang Y, Liu T, Davis CM, Ehli EA, Tan L, Zhou F, Hu J, Yu Y, Chen X, Nguyen TM, Rosen JM, Hawke DH, Ji Z, Chen Y Nat Commun 2017 Nov 8 1 1749
- EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
- Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC Oncogene 2017 Sep
- Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer.
- Zhao X, Huffman KE, Fujimoto J, Canales JR, Girard L, Nie G, Heymach JV, Wistuba II, Minna JD, Yu Y J. Am. Soc. Mass Spectrom. 2017 Jul
- Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.
- Eskiocak B, McMillan E, Mendiratta S, Kollipara R, Zhang H, Humphries C, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales T, Eskiocak U, Smith MP, Sudderth J, Komurov K, DeBerardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White M Cancer Discov 2017 Apr
- Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export.
- Shi KY, Mori E, Nizami ZF, Lin Y, Kato M, Xiang S, Wu LC, Ding M, Yu Y, Gall JG, McKnight SL Proc. Natl. Acad. Sci. U.S.A. 2017 Jan
- PARP-1 Controls the Adipogenic Transcriptional Program by PARylating C/EBPß and Modulating Its Transcriptional Activity.
- Luo X, Ryu KW, Kim DS, Nandu T, Medina CJ, Gupte R, Gibson BA, Soccio RE, Yu Y, Gupta RK, Kraus WL Mol. Cell 2017 Jan 65 2 260-271
- The Emerging Function and Mechanism of ceRNAs in Cancer.
- Wang Y, Hou J, He D, Sun M, Zhang P, Yu Y, Chen Y Trends Genet. 2016 Feb
Honors & Awards
- R35 MIRA award
- Special issue of Future of Biochemistry
- Developmental Research Program Award
NCI Lung Cancer SPORE (Specialized Programs of Research Excellence) (2017)
- Young Investigator Award
Chinese American Diabetes Association (2017)
- ACS Research Scholar
American Cancer Society (2015)
- CPRIT Scholar in Cancer Research
Cancer Prevention Research Institute of Texas (2011)
- University of Texas STARS award
University of Texas System (2011)
- Virginia Murchison Linthicum Scholar in Medical Research
UT Southwestern Medical Center (2011)
- Tuberous Sclerosis Alliance Postdoctoral Fellowship
Tuberous Sclerosis Alliance (2008)
- Chun-Tsung Scholar
Chun-Tsung Endowment (1999)
- American Association for Cancer Research (2013)
- American Society for Mass Spectrometry (2001)